Agents | Phase | Participants | Dose | Outcome | Refs. |
---|---|---|---|---|---|
Atezolizumab Bevacizumab | 2 | 305 | 1200Â mg 15Â mg/kg | Improved PFS, which had no association with tumor mutation and neoantigen burden | [179] |
Atezolizumab Bevacizumab | 3 | 915 | 1200 mg 15 mg/kg | Improved PFS versus sunitinib (11·2 months versus 7.7 months) with a favorable safety profile | [175] |
Atezolizumab Cabozantinib | 1b | 102 | 1200 mg 40–60 mg | Prolonged PFS to19.5 months | [226] |
Atezolizumab Bevacizumab | 2 | 59 | 1200Â mg 15Â mg/kg | Improved PFS (8.7 moths) with detection of TRAEs in 83% of patients | [227] |
Atezolizumab Interferon-α | 1b | 158 | 1200 mg 180 μg | Significant ORR (20.0%) | [184] |
Atezolizumab | 1 | 17 | 0.01–20 mg/kg | Improved OS (28.9 months) and PFS (5.6 months) | [177] |
Atezolizumab Navoximod | 1 | 157 | 50–1000 mg | Acceptable safety, tolerability, and pharmacokinetics | [228] |
Avelumab Axitinib | 3 | 886 | 10Â mg/kg 5Â mg | Prolonged PFS and OS versus sunitinib which was in association with below-median NLR | |
Atezolizumab A2AR antagonist | 1 | 68 | 840 mg 50–100 mg | A durable clinical benefit associated with increased CTLs infiltration into the tumor | [230] |